AP
FATE icon

AlpInvest Partners’s Fate Therapeutics FATE Stock Holding History

AlpInvest Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,104
Closed -$371K – 30
2019
Q1 		$371K Sell
21,104
-5,821
-22% -$91.9K 0.5% 22
2018
Q4 		$345K Buy
+26,925
New +$375K 0.99% 18

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AlpInvest Partners's FATE Position: Q2 2019 in Review

AlpInvest Partners sold out of Fate Therapeutics (FATE) in Q2 2019, closing a stake of 21,104 shares — an estimated $371K sold.

AlpInvest Partners first reported a position in FATE in Q4 2018 and held it in 2 quarters. The position peaked at $371K in Q1 2019. 136 funds tracked by Wall St. Rank hold FATE as of Q2 2019.

  • AlpInvest Partners reported no remaining Fate Therapeutics position as of Q2 2019 after selling out during the quarter.
  • AlpInvest Partners sold 21,104 Fate Therapeutics shares in Q2 2019, an estimated $371K.
  • AlpInvest Partners first reported a position in Fate Therapeutics in Q4 2018 and held it in 2 quarters.
  • AlpInvest Partners's Fate Therapeutics position peaked at $371K in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2019.

Based on AlpInvest Partners's 13F filing for Q2 2019, filed 13 Aug 2019.